share_log

Tonix Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer SAENGER BRADLEY

SEC announcement ·  Mar 1 06:14
Summary by Futu AI
Bradley Saenger, the Chief Financial Officer of Tonix Pharmaceuticals Holding Corp. (TNXP), has engaged in a transaction involving the company's stock. The action took place on February 27, 2024. However, the announcement did not disclose the number of shares transacted, the nature of the shares, the transaction price, or the total value of the shares. Additionally, the number of shares held by Saenger after the transaction was not provided. This information is typically crucial for investors to assess the significance of insider transactions within a company.
Bradley Saenger, the Chief Financial Officer of Tonix Pharmaceuticals Holding Corp. (TNXP), has engaged in a transaction involving the company's stock. The action took place on February 27, 2024. However, the announcement did not disclose the number of shares transacted, the nature of the shares, the transaction price, or the total value of the shares. Additionally, the number of shares held by Saenger after the transaction was not provided. This information is typically crucial for investors to assess the significance of insider transactions within a company.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.